|
|
|
| Evaluating The Decisions That Shape mRNA Success | 09.30.26 | This session explores the critical decisions that drive successful mRNA therapy and vaccine development. Attendees will gain practical insights into challenges related to manufacturing, raw materials, formulation, supply chains, and regulatory expectations. The discussion will highlight strategies for optimizing mRNA design, process development, facility planning, and production workflows to build robust, scalable, and well-characterized manufacturing programs. Learn more. |
|
|
|
|
How well do we know our mRNA-LNP drug products today? In this discussion, Advancing RNA panelists unpack what we continue to learn about the analytical methods we have at our disposal today, while identifying which attributes we should be paying closer attention to today. |
|
|
|
A conversation with Samir Ounzain, Ph.D., HAYA Therapeutics | Explore how the regulatory genome and lncRNAs are shifting RNA medicine beyond protein targets, enabling cell-state reprogramming to treat disease at its source. | |
|
|
|
A conversation with Art Krieg, Zola Therapeutics | RNA/DNA immunotherapy may overcome liver metastases by reprogramming innate immunity, restoring interferon signaling, and improving responses to checkpoint inhibitors. | |
|
|
|
By Ahmet C. Berkyurek, Ph.D., CamMed Therapeutics Ltd. | European RNA biotech leaders can accelerate U.S. success by aligning fundraising, partnerships, manufacturing, hiring, and regulatory strategy from day one. | |
|
|
|
A conversation with Dan Williams, Ph.D., SynaptixBio | SynaptixBio CEO Dan Williams explains why funding, regulatory strategy, toxicology, and disciplined execution — not just science — determine success in advancing ultra-rare ASO therapies. | |
|
|
|
|
| dsRNA: Why Polymerase Choice Matters | Article | Primrose Bio | Polymerase selection during IVT shapes dsRNA levels, processing costs, and product quality. See how enzyme engineering reduces abortive transcripts and improves purity profiles for complex mRNA manufacturing applications. |
|
|
| Screening T7 Polymerases To Optimize xRNA Yield And Quality | Article | By Jing Zhu, Ph.D., Recipharm Advanced Bio | Discover how the evolution of T7 polymerase is optimizing in vitro transcription for RNA therapeutics. Learn to balance performance, cost, and supply to make smart choices for your xRNA manufacturing. |
|
|
|
|
|
|
|
|
|
|
.png){kind=logo}
